Key result
ShengMai-San attenuates diabetic myocardial injury and oxidative stress via AMPKα activation and NOX inhibition.
Why the study?
ShengMai-San (SMS) shows cardioprotective effects in diabetic animals, but the underlying mechanisms remained to be fully elucidated.
Does ShengMai-San attenuate cardiac remodeling and oxidative stress in a rat model of diabetic cardiomyopathy?
Does ShengMai-San attenuate cardiac remodeling and oxidative stress in a rat model of diabetic cardiomyopathy?
p-value: p=<0.01
ShengMai-San attenuates diabetic cardiomyopathy in rats by reducing NOX-mediated oxidative stress and activating AMPKα.
Does not support clinical use; leaves open translation of ShengMai-San for diabetic cardiomyopathy pending human trials.
BACKGROUND AND PURPOSE: ShengMai-San (SMS) is traditionally used to treat ischemic cardiovascular and cerebrovascular diseases. Recently, several studies have reported the cardioprotective effects of SMS in diabetic animals. However, the potential mechanisms have not yet been fully elucidated. In this study, we investigated whether SMS exerts a beneficial effect in diabetic cardiomyopathy (DCM) by alleviating NADPH oxidase (NOX)-mediated oxidative stress. METHODS: SD rats were randomly divided into a negative control group (NC), diabetes mellitus group (DM) and SMS-treated group (SMS). The myocardial structure alterations, apoptosis and biomarkers of oxidative stress were observed. Moreover, to explore the protective mechanism of SMS, the activation of AMPKα, expression and translocation of NOX-related proteins were assessed. RESULTS: Diabetes led to excessive collagen content, fibrosis, and apoptosis in the myocardium. Oxidative stress in diabetic hearts was indicated by low levels of T-AOC, high levels of 8-iso-PGF2α and 8-OHdG, inactivation of AMPKα, elevated expression of NOX2 and NOX4 and translocation of NOX isoforms p47phox and p67phox. Treatment with SMS for 10 weeks resulted in the alleviation of diabetes-associated myocardial structure abnormalities and apoptosis. Additionally, SMS attenuated the accumulation of oxidative stress markers in myocardial tissue. Further investigation showed that SMS was able to reverse the levels of oxidative stress-associated proteins NOX2 and NOX4 in the DM rats. Moreover, SMS treatment blunted the translocation of NADPH oxidase isoforms p47phox and p67phox as well. Furthermore, SMS promoted the activation of AMPK in the cardiac tissue of diabetic rats. CONCLUSION: These findings indicate that SMS exhibits therapeutic properties against diabetic cardiomyopathy by attenuating myocardial oxidative damage via activation of AMPKα and inhibition of NOX signaling.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2021) studied Diabetic cardiomyopathy (n=45). ShengMai-San (SMS) vs. Normal saline (untreated diabetic group) was evaluated on Cardiomyocyte apoptosis and oxidative stress markers (including NOX expression) (p=<0.01). ShengMai-San significantly attenuated diabetes-associated myocardial structural abnormalities, apoptosis, and oxidative stress by activating AMPKα and inhibiting NOX signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: